Lepu Biotechnology

Jul 3, 2019

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas 2:42 PM Share Shiyu Capital leads Lepu’s $131M A round  Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing investor Lepu Medical Technology (Beijing) Co. Ltd. (SZSE:300003) participated in the financing. Founded last year, Lepu has PD-1 and PD-L1 inhibitors, an oncolytic virus and multiple antibody-drug conjugates (ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors  Citryll B.V. (Oss, the Netherlands) raised €15 million ($16.9 million) in a series A round from ModiQuest B.V. (Oss, the Netherlands), BOM Brabant Ventures, the BrightGene International (Hong Kong) Ltd. unit of BrightGene Bio-medical technology Co. Ltd. (Suzhou, China) and Curie Capital. The company is developing antibodies that block the formation of neutrophil extracellular traps by binding to N-terminal citrullinated epitopes in histones, which could treat autoimmune diseases such as lupus and rheumatoid arthritis. Jibeier looks to list in Shanghai  The Shanghai Stock Exchange accepted an application from Jiangsu Jibeier Pharmaceutical Co. Ltd. (Zhenjiang, China) to list on its new science and technology innovation board. The company proposed to raise up to RMB690 million ($100.2 million). The pharma develops chemical preparations and traditional Chinese medicines. Calliditas raises $22.6M  A year after going public on NASDAQ Stockholm, renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK210.3 million ($22.6 million) through the sale of 3.5 million shares at SEK60 in a private placement. Investors included BVF Partners L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). User Sign in